Business
Half Yearly Report
Half Yearly Report.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0850N Scancell Holdings Plc 27 January 2016 \n\n27 January 2016\n \nScancell Holdings Plc\n \nInterim Results for the six months ended 31 October 2015\n \nScancell focuses on the US in a transformational year\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces its interim results for the six months ended 31 October 2015. \n \nHighlights:\n \n· Completion of the main study period of the Phase 1/2 clinical trial of SCIB1 ImmunoBody® in patients with Stage III/IV melanoma with continued strong survival data\n− All 20 patients with resected disease remain alive\n− Median observation time in 16 patients who received 2-4mg is now 42 months since study entry and 11 remain disease free\n− Median observation time in four resected patients who received 8mg is 10 months and all remain disease free\n− All nine patients currently on long-term treatment remain disease free up to 39 months from start of SCIB1 treatment\n− Final clinical study report expected in H1 2016\n \n· Continued good progress in development of lead product, Modi-1, from Moditope® platform\n− Improvement in peptide components suggest Modi-1 will be effective in up to 95% of patients with triple negative breast and ovarian cancers\n− Clinical studies anticipated to commence in 2017\n− Important paper outlining the scientific basis for the Moditope® platform published in revered cancer journal, Cancer Research\n \n· Loss for the six month period of £1.17 million (2014: loss: £1.34 million)\n \n· Group cash balance at 31 October 2015 was £1.81 million (30 April 2015: £3.06 million)\n \nPost Period Highlights:\n \n· Prestigious US scientific team to lead Phase 2 checkpoint inhibitor combination study with SCIB1, expected to commence in 2017\n \n· &nb...